About the Session
In this session, hear from SVP of Science, Anthony Schmitt, PhD, and learn about how the 3D genome reveals novel disease mechanisms and therapeutic targets missed by other technologies.
A New Frontier in Biomarker Discovery – how the 3D genome reveals novel disease mechanisms and therapeutic targets missed by other technologies
- How 3D genomic technologies enable scientists to uncover novel disease mechanisms and identify new therapeutic targets.
- How 3D genomics is enabling biomarker discovery, tumor classification, and patient stratification.
- How 3D genomics is revealing genetic drivers of previously undiagnosed tumors, reshaping how we understand disease, and yielding exciting new opportunities in precision oncology.
Anthony Schmitt, PhDSVP, Science at Arima Genomics
Anthony Schmitt, PhD, is the Senior Vice President of Science at Arima Genomics – a San Diego based biotech focused on advancing human health through the power of 3D genomics. Under his leadership, Arima has launched multiple products enabling life science researchers to explore the 3D genome using a range of applications – from genome assembly to translational cancer research and beyond. Prior to Arima, Anthony received his PhD from the University of California, San Diego, where he developed novel methodologies to understand mechanisms of gene regulation. Anthony is an accomplished scientist who has published his work in leading peer-reviewed scientific journals.